Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218

OBJECTIVE: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gynecol Oncol
Autori principali: Wade, K.N. Slaughter, Brady, M.F., Thai, T., Wang, Y., Zheng, B., Salani, R., Tewari, K.S., Gray, H.J., Bakkum-Gamez, J.N., Burger, R.A., Moore, K.N., Bookman, M.A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7048388/
https://ncbi.nlm.nih.gov/pubmed/31409486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2019.07.020
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi